CA-GLOBAL-CRITICAL-LOGIS
1.2.2024 14:01:33 CET | Business Wire | Press release
Rock-it Cargo, a Global Critical Logistics (GCL) company and the global leader in end-to-end logistics for live events and high net worth goods, today announced the acquisition of SOS Global (SOS), the North Carolina-based freight forwarder, from NEP Group. The combined company will be the largest global specialty logistics provider in the live touring and sports and broadcast markets. The acquisition closed on January 31, 2024, and terms were not disclosed.
Rock-it’s core leadership in live music touring has been enhanced in recent years by diversifying into and significantly growing in the sports and broadcast, film and TV production, and high net worth goods sectors. Rock-it and its sister companies have offices in 18 countries and, in 2023, completed shipments in more than 115 countries. Rock-it leverages its unparalleled network and experience to deliver end-to-end solutions for its customers in every market with the same personal touch and “failure is not an option” ethos that has permeated Rock-it since its founding in 1978 with first clients Uriah Heep and Led Zeppelin.
SOS specializes in freight forwarding and logistics services for live events, particularly in the sports and broadcast industries. They service every major US sports and news broadcaster, the largest US professional sports leagues, and many of the largest vendors to these companies. Based in New Bern, NC, SOS prioritizes speed and control in its deliveries with additional offices across the United States, Canada, Germany, United Kingdom, and the United Arab Emirates.
“Today we bring together two trusted brands with a combined 83 years of experience,” said Daniel Rosenthal, President and CEO of GCL. “For 38 years, customers have known they can ‘SOS’ their most valuable goods via a 24/7/365 operational hub. SOS’s legacy will be strengthened as part of Rock-it Cargo, with expanded services and global access via our unrivaled network. I have been thrilled to get to know Ed Reno and the SOS team, and I cannot wait to grow our business and serve our customers better together. The breadth, depth and skills of Rock-it and SOS is unparalleled in global live performance touring and live sporting events.”
The acquisition aligns with GCL’s strategic plans to strengthen Rock-it’s global position within the sports and broadcast sector, as well as enhance its domestic capabilities in the live touring, events, film and theater categories. In 2023, more than 85% of GCL’s revenue was earned from international shipments, whereas a majority of SOS’s revenue was earned domestically.
Ed Reno, president of SOS, who will remain with GCL and report directly to Rosenthal, said, “Our team is very excited to combine forces with Rock-it. SOS brings a robust domestic network and operational capabilities designed to meet the needs of our sports and broadcast clients. Joining a larger international specialty logistics leader will be good for our customers and good for our team.”
GCL has made several acquisitions recently to bolster its global capabilities serving the live touring, sports, broadcast, film and TV production, fine art, and classic and high-value automobile sectors. This buying spree includes the acquisitions of Classic Automotive Relocation Services (CARS), the largest global transporter of high-value automobiles, and Dynamic International, one of the top international logistics providers for film and TV productions.
ABOUT GLOBAL CRITICAL LOGISTICS (GCL)
Headquartered in Los Angeles CA, Global Critical Logistics (GCL) is a global leader in live event entertainment logistics and high net worth logistics and freight. It is the holding company for a family of brands, including Rock-it Cargo, Dietl, Dynamic International, CARS, SOS, Cosdel, Xtreme, and Dell Will.
Focused on high-touch, mission-critical air, ocean, and surface freight forwarding and logistics services, the GCL family of leading brands work with customers across the live entertainment, music touring, sports, motor sports, corporate events, theatre, tradeshow, fine art, film and TV production, broadcast, classic and high-end automobiles, and industrial project end markets.
GCL has offices in North and South America, Europe, the Middle East, Oceania, and Asia, augmented by a network of long-term partner agents specializing in critical logistics.
The companies of GCL serve thousands of customers annually, and have provided bespoke, specialized logistics solutions for the most demanding transportation requirements across every continent for over 45 years.
GCL is backed by ATL Partners, a premier sector-focused private equity firm that invests in aerospace, transportation, and logistics and is based in New York.
For more information, please visit, gcl.global.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201662351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom